Fresenius Kabi AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fresenius Kabi AG
Fresenius Kabi has set out launch plans after receiving its first US biosimilar approval, for its Stimufend pegfilgrastim rival to Neulasta.
Keeping Track: US FDA Novel Approvals Return With Xenpozyme, Spevigo Nods; Stimufend Survives COVID-19 Delays
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Fresenius Kabi has followed a US filing for its MSB11456 proposed tocilizumab biosimilar with a parallel marketing authorization application in the EU for its rival to RoActemra.
Fresenius Kabi has struck a deal with Brazilian organizations Fiocruz/Bio-Manguinhos and Bionovis to supply its Idacio biosimilar adalimumab rival to Humira for the next ten years.
- Generic Drugs
- Infusion Therapy Equipment and Supplies
- Other Names / Subsidiaries
- mAbxience S.L.